)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Camp4 Therapeutics (CAMP) investor relations material
Camp4 Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Focused on developing RNA-targeting therapeutics for genetic diseases, with lead programs in SYNGAP1-related disorders and urea cycle disorders (UCDs).
Advanced CMP-SYNGAP-01 preclinical program, presenting positive translational data showing efficacy in humanized mouse models and increased protein in non-human primates.
Completed dosing in the third MAD cohort for CMP-CPS-001 and highlighted interim safety results from the ongoing Phase 1 UCD trial.
Entered strategic collaborations with BioMarin and Fulcrum, generating milestone and collaboration revenue.
Completed IPO in October 2024, raising $72.4 million in net proceeds and converting all outstanding preferred stock to common stock.
Financial highlights
Research and collaboration revenue of $1.5 million for Q2 2025, up from $0 in Q2 2024, driven by BioMarin and Fulcrum agreements.
Net loss of $12.6 million for Q2 2025, unchanged from Q2 2024.
Operating expenses increased to $14.5 million in Q2 2025 from $12.7 million in Q2 2024, mainly due to higher R&D and G&A costs.
Cash, cash equivalents, and marketable securities were $39.1 million as of June 30, 2025, down from $49.3 million as of March 31, 2025.
Accumulated deficit reached $236.8 million as of June 30, 2025.
Outlook and guidance
Cash runway expected to fund operations into Q2 2026, but substantial doubt exists about ability to continue as a going concern without additional capital.
Plans to initiate GLP toxicology studies for CMP-SYNGAP-01 in Q3 2025 and a global Phase 1/2 trial in 2026, pending regulatory clearance.
Data from all four SAD cohorts and first three MAD cohorts of CMP-CPS-001 Phase 1 trial expected in Q4 2025, with potential for partnership discussions.
When is the SYNGAP1 Phase 1/2 trial expected?
What is the strategy for CMP-CPS-001 post-Q4 data?
How long can current cash fund operations?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Camp4 Therapeutics earnings date
Q3 202514 Nov, 2025
Next Camp4 Therapeutics earnings date
Q3 202514 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Camp4 Therapeutics Corp is a biotechnology company focused on developing RNA-based therapeutics. The company leverages a proprietary platform to identify and regulate gene expression through RNA technologies, aiming to address a range of diseases driven by dysregulated gene activity. Camp4 Therapeutics' research and development activities span multiple therapeutic areas, applying its platform to discover potential treatments targeting specific genetic mechanisms. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage